The ₹10,000 crore allocation for non-communicable diseases under Biopharma Shakti marks a significant step toward strengthening India’s healthcare ecosystem. With rising cases of Non-Communicable Diseases such as diabetes, cardiovascular conditions, and cancer, this investment is expected to boost research, innovation, and access to advanced treatments.
Experts believe the initiative will accelerate drug development, improve early diagnosis, and enhance healthcare infrastructure. It also signals a shift toward preventive and precision medicine. Effective implementation and collaboration between public and private sectors will be key to maximizing its long-term impact on population health.
